Latest News - Moderna
Top Corporates Hub
Moderna
This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative.
27.05.2026 15:07
BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.
Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
27.05.2026 10:57
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
26.05.2026 10:16
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
3 Cash-Burning Stocks with Open Questions
23.05.2026 09:56
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot
21.05.2026 16:45
The Food and Drug Administration is eyeing a meeting on June 18 to discuss mRNA-1010.
How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones
20.05.2026 03:13
Roivant Sciences has seen only a marginal shift in its modeled fair value, from US$35.67 to US$35.71, keeping the headline price target effectively stable. That small move reflects a tug of war in analyst commentary, with optimism around the US$2.25b Genevant and Arbutus settlement and key brepocitinib milestones set against questions about how much of this is already in the stock. Read on to see how to track these shifting views and what to watch as the Roivant story continues to...
What's going on in today's session: S&P500 gap up and gap down stocks
19.05.2026 14:35
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
19.05.2026 12:20
Moderna, Inc. (MRNA) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP &...
Cramer’s Stop Trading: Zoom Communications
19.05.2026 10:01
CNBC’s Jim Cramer explains why he is keeping an eye on shares of Zoom Communications.
25. Lila Sciences
19.05.2026 05:50
Lila Sciences, a "superintelligence platform" with a focus on scientific advances, ranks No. 25 on CNBC’s 2026 Disruptor 50 list.
Assessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research Attention
16.05.2026 16:13
Moderna (MRNA) is back in focus after Phase 3 data showed its mRNA flu vaccine outperformed standard shots in older adults, while separate hantavirus research tied to a cruise ship outbreak added further attention. See our latest analysis for Moderna. The latest flu and hantavirus updates come after a powerful run, with the stock showing a 58.91% year-to-date share price return and a very large 1-year total shareholder return. However, longer-term total shareholder returns over 3 and 5 years...
Hantavirus: Is there a risk of another pandemic?
16.05.2026 04:25
Investing.com -- Moderna Inc (NASDAQ:MRNA) shares rallied 13% over a multi-day period following reports of a localized Hantavirus outbreak aboard the cruise vessel MV Hondius.
Salesforce Pushes Agentic AI Into Core Workflows With New Deployments
16.05.2026 01:19
Salesforce (NYSE:CRM) is rolling out new agentic AI deployments across core enterprise workflows. The company has launched Agentforce Contact Center with Ribbon Communications and AI-driven communications integrations at scale. Salesforce has partnered with Moderna to support global operations through Agentforce Life Sciences. The company has also introduced new e-signature integrations with Syncfusion to extend workflow coverage. These moves put Salesforce's AI platform directly into front...
3 Cash-Heavy Stocks with Warning Signs
14.05.2026 06:28
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Explore the top gainers and losers within the S&P500 index in today's session.
13.05.2026 19:05
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
13.05.2026 11:30
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage
Moderna Is a Money-Losing Vaccine Maker. It’s Also the Ultimate Stock Hedge.
13.05.2026 08:08
Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.
Moderna (MRNA) Shares Skyrocket, What You Need To Know
13.05.2026 03:32
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clinical trial results for its seasonal flu vaccine candidate, mRNA-1010, and announced positive Phase 1 data for its hantavirus vaccine.
MODERNA : Jefferies reiterates its Neutral rating
12.05.2026 02:21
Jefferies's research confirms his advice and maintains his neutral opinion on the stock. The target price continues to be set at USD 45.
MODERNA : Jefferies reiterates its Neutral rating
12.05.2026 02:21
Jefferies's research confirms his advice and maintains his neutral opinion on the stock. The target price continues to be set at USD 45.